文献速递免疫规划妇幼与学校卫生

不同组合DTaP疫苗不增加婴儿30天死亡风险

Use of different combination diphtheria-tetanus-acellular pertussis vaccines does not increase risk of 30-day infant mortality. A population-based linkage cohort study using administrative data from the Australian Childhood Immunisation Register and the National Death Index.
PubMed 文献 · Vaccine · 2018-11-28

该研究基于澳大利亚儿童免疫登记和全国死亡索引链接数据,纳入1999至2010年间在2、4、6月龄接种三价、四价或六价DTaP联合疫苗的婴儿队列。结果显示30天全因死亡率低,且与三价DTaP相比,四价或六价DTaP未升高全因或非特异性死亡风险。结论认为常规DTaP联合疫苗不增加婴儿死亡风险。

要点

  • 2、4、6月龄接种不同组合DTaP疫苗未增加30天全因死亡风险。
  • 四价或六价DTaP相比三价DTaP未升高非特异性死亡风险。
  • 30天全因死亡率从2月龄队列的127.4降至6月龄队列的59.3/10万人年。

核心结论

  • 常规DTaP联合疫苗在生命前六个月接种与婴儿死亡无关。

研究设计与样本

  • 观察性全国队列研究,链接澳大利亚儿童免疫登记与全国死亡索引数据。
  • 纳入1999年1月至2010年12月在2、4、6月龄接种三价、四价或六价DTaP联合疫苗的婴儿。

主要发现

  • 30天全因死亡率低,从2月龄队列的127.4降至6月龄队列的59.3例/10万人年。
  • 与三价DTaP相比,任何四价或六价DTaP疫苗在任何队列均未观察到全因或非特异性死亡风险升高。

临床怎么用

  • 可为家长和公共卫生人员提供证据:常规DTaP联合疫苗不增加婴儿死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether differences in combination DTaP vaccine types at 2, 4 and 6 months of age were associated with mortality (all-cause or non-specific), within 30 days of vaccination. DESIGN: Observational nationwide cohort study. SETTING: Linked population data from the Australian Childhood Immunisation Register and National Death Index. PARTICIPANTS: Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6 months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3 million children in the 2, 4 and 6 month vaccine cohorts, respectively. MAIN OUTCOME MEASURES: Infants were evaluated for the primary outcome of all-cause mortality within 30 days. A secondary outcome was non-specific mortality (unknown cause of death) within 30 days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 'Sudden infant death syndrome', R96 'Other sudden death, cause unknown', R98 'Unattended death', R99 'Other ill-defined and unspecified cause of mortality' or where no cause of death was recorded. RESULTS: The rate of 30 day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6 month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort. CONCLUSION: Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Duszynski KM, Pratt NL, Lynch JW, et al. Use of different combination diphtheria-tetanus-acellular pertussis vaccines does not increase risk of 30-day infant mortality. A population-based linkage cohort study using administrative data from the Australian Childhood Immunisation Register and the National Death Index. Vaccine. 2018. PMID: 30503081. doi:10.1016/j.vaccine.2018.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。